Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™for all indicationsmatching the reference product ...
PharmiWeb22h
AI in Drug Discovery: Increasing Success Rates by 20%
The average drug takes 10+ years and $2.3B to bring to market—with a 90% failure rate in clinical trials. AI is rewriting this equation. By 2025, AI-driven drug discovery is projected to slash ...